ПАРАКВАТ-ИНДУЦИРОВАННАЯ МОДЕЛЬ ПАРКИНСОНИЗМА И ВЫЯВЛЕНИЕ ФОСФОРИЛИРОВАННОГО α-СИНУКЛЕИНА В ЭНТЕРАЛЬНОЙ НЕРВНОЙ СИСТЕМЕ У КРЫС

А. В. Ставровская, Д. Н. Воронков, К. А. Кутукова, М. В. Иванов, А. С. Гущина, С. Н. Иллариошкин

Научный центр неврологии, Москва, Россия

Паркинсонизм (БП) — распространенное нейродегенеративное заболевание с широким спектром моторных и немоторных нарушений. Немоторные симптомы (в частности, нарушения функций желудочно-кишечного тракта) обычно опережают манифестацию моторных проявлений на 5–15 лет. Характерный признак БП, цитоплазматические агрегаты фосфорилированного белка при системном многократном введении крысам паракват (до доз 6 mg/kg) были выявлены нами в мотонейронах (достоверное увеличение на 50% (p = 0,033) и 20% (p = 0,01)) в области мотонейронах мотонейронах экспериментальных крыс. Кроме того, было обнаружено снижение двигательной активности в открытой лабиринте на 20% (p = 0,04) и увеличение продолжительности неврологических тестов (уровень значимости p < 0,01). Нами установлено, что паракват может быть очень перспективным для моделирования БП.

Ключевые слова: болезнь Паркинсона, моделирование на животных, α-синуклеинопатии на ранней стадии экспериментального паркинсонизма, α-синуклеин, при системном многократном введении крысам паракват (до доз 6 mg/kg). Экспериментальные крысы были поделены на группы: контрольная и экспериментальная группа. В контрольной группе использовались крысы, в группе экспериментальной крысы подвергались воздействию параквата (до 6 mg/kg в течение 6 месяцев). Крысам проводили эксперименты по определению двигательной активности, нарушения биохимических показателей и изменения морфологической структуры нейронов. Полученные данные демонстрируют снижение двигательной активности у экспериментальных животных, а также увеличение продолжительности неврологических тестов.

Финансирование: работа поддержана грантом РФФИ № 19-15-00320.

Благодарности: авторы выражают благодарность сотрудникам лаборатории экспериментальной патологии нервной системы А. С. Ольшанского и Н. Г. Ямщикову за вклад в работу.

Поступила 12.08.2019. Рецензия принята к печати 26.08.2019. Опубликована онлайн 13.09.2019.
Parkinson's disease (PD) is a widespread neurological disorder most common in people over > 60 years of age. It is estimated that at least 4 million individuals are affected worldwide. Today, the world's population is aging, and PD prevalence is expected to double by 2040 [1]. In the absence of curative treatment, the focus should be placed on researching the underlying molecular mechanisms of PD in animal models.

Typical motor symptoms of PD (bradykinesia, rigidity, resting tremors) are linked to the loss of dopaminergic neurons in substantia nigra pars compacta, nigrostriatal pathway degeneration and progressive neurotransmitter imbalance in the central nervous system (CNS) [2]. Non-motor features comporory of PD; these can be induced by the powerful non-selective herbicide paraquat (1,1-dimethyl-4,4-bipyridinium dichloride). Paraquat is widely used for controlling noxious weeds that invade orchards, agricultural lands, coffee, tea and cocoa plantations, as well as for desiccating crops [6, 8, 9]. It bears resemblance to 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of the well-known neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This makes paraquat suitable for modeling PD in animals. The toxic effect of paraquat is linked to the production of superoxide radicals; at the same time, paraquat can be metabolized by the powerful non-selective herbicide paraquat (1,1-dimethyl-4,4-bipyridinium dichloride). Paraquat is widely used for controlling noxious weeds that invade orchards, agricultural lands, coffee, tea and cocoa plantations, as well as for desiccating crops [6, 8, 9]. It bears resemblance to 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of the well-known neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This makes paraquat suitable for modeling PD in animals.

Studied exploiting animal models of PD usually involve long-term exposure to paraquat administered systemically at 10 mg/kg. Such regimens result in pronounced motor impairment in the animals and cause significant degeneration of dopamine-producing neurons in the substantia nigra [10]. This approach cannot be applied to obtain information about the early stages of PD or to assess non-motor symptoms that precede the onset of motor impairment. This study aimed to identify a complex of prodromal symptoms observed in the experimental animals in the early stage of induced PD.

METHODS

The study was conducted in male Wistar rats (n = 18) aged 3–3.5 months (the 12/12 light/dark cycle) and had free access to food and water. The animals were stratified into the main (paraquat) group (n = 10) and the control group (n = 8). Paraquat was dissolved in normal saline; 0.5 ml (6 mg/kg) of the obtained solution were administered to the animals from the main group on alternate days over the course of 4 weeks. The control group received an equal amount of normal saline. The next day after the last injection, the open field test (OPT) and the tapered beam walking test (BTW) were conducted to assess locomotor activity in the animals. The initial level of motor activity was measured in intact rats before the experiment. The open field arena was fabricated in the workshop of Research Institute of Neurology. It was a cube-shaped 75 x 75 x 40 cm box; its floor was divided into 25 equal squares. During the open-field test, we measured the distance each rat covered within 3 minutes. The beam-walking apparatus (open beam) was 2 cm wide of 165-cm long beams; the bottom beam was 10 to 5.5 cm in width; the lower beam, 6 to 1.5 cm; the height was 2 cm for both beams. The enclosure at the narrow end of the walking bridge had a removable lid and a hole in the front panel to allow the animal inside. The apparatus was installed 70 cm above the floor. The rat traveled along the top beam from its far end towards the safe enclosure. For each animal, we counted the number of slips from the top beam throughout the entire route and the total number of steps made by each paw. The experiment was recorded using the Any-maze video-tracking system (Stoelting Inc.; USA).

Four brain tissue samples were selected from each group for further histopathologic examination. Briefly, the brain was removed and fixed in 4% formalin. The samples were soaked in O.C.T. compound (TissueTek; USA); a series of 10-µm frontal sections was prepared in a Tissue-Tek Cryo3 Flex cryostat (Sakura Finetek; USA). The slides were immunofluorescently stained in order to determine tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP) content in the tissue. TH is a common marker for dopaminergic neurons, while decrease of GFAP indicates neurodegeneration in the nigrostriatal system. Cell nuclei were stained with DAPI. TH content was determined using polyclonal rabbit antibodies (1 : 500, Sigma; Germany) and CF488-conjugated goat secondary antirabbit antibodies (1 : 500, Sigma; Germany). GFAP levels were estimated using Cys3-conjugated antibodies (1 : 80; Sigma). We examined 5 to 10 slides of each brain sample prepared from the tissue along the rostrocaudal axis at the level of the caudate nuclei and substantia nigra. The slides were studied under the Eclipse NIU fluorescence microscope (Nikon; Japan). The density of TH-positive fibers was estimated in manually delineated regions at x40 magnification in ImageJ (Wayne Rasband, NIH; USA); the mean fluorescence intensity of striatal tissue was corrected to background fluorescence.

Five to seven cm-long regions of the jejunum were excised and dissected in the longitudinal plane following the mesentery course, washed in normal saline and spread out on the paraffin-coated bottom of Petri dishes. The specimens were fixed in 4% buffered formalin for 3 h and then washed in a phosphate buffer (pH = 7.4). After that, the mucosal lining and the underlying submucosal layer were removed with ophthalmic forceps; the procedure was carried out under the Wild M7A stereomicroscope (Wild Heerbrugg; Germany). Fluorescence assays were performed on the obtained samples of the jejunum constituted of circular and longitudinal muscle fibers and the myenteric plexus. Primary antibodies to class III β-tubulin, TH and serin-129-phosphorylated α-synuclein (α-Syn-p129) taken at 1 : 250 dilutions were used to identify nervous fibers in the myenteric plexus. Visualization of binding reactions was aided by secondary CF448-conjugated antibodies (Sigma; Germany) taken at a 1 : 100 dilution. The samples were examined and photographed using Nikon Eclipse NIU (Nikon; Japan).
equipped with a Nikon DS-Qi digital camera (Nikon; Japan). Morphometric measurements were done in NIS Elements (Nikon; Japan) using images obtained at ×10 magnification in at least 30–40 fields of view per animal. The mean fluorescence intensity and brightness (corrected to background staining) of the myenteric plexus fibers positive for class III β-tubulin and TH were measured in the NIS Elements software.

The obtained data were analyzed in Statistica 12 (StatSoft; USA); one-way ANOVA was followed by Fisher’s exact test and Mann-Whitney U test for post-hoc comparisons. The differences were considered significant at \( p < 0.05 \).

RESULTS

Each experimental animal received a total of 12 paraquat injections. The initial distance travelled by the intact rats in the open field was 4.96 ± 0.7 m. The next day after the last injection, OFT revealed a decline in motor activity in the rats who had been exposed to paraquat, but the differences between the groups were insignificant (Fig. 1).

BWT demonstrated poor motor coordination in the rats from the main group manifesting itself as a statistically significant increase in the number of slips from the top beam made by left paws (Fig. 2). The number of slips was expressed as percentage from the total number of steps made by the corresponding limb.

The intensity of staining for TH was decreased in the substantia nigra of the animals who had been receiving paraquat injections; the histopathologic examination revealed damage to dopaminergic neurons. The most pronounced changes were observed in the striatum. The intensity of TH-positive staining in striatal tissue was significantly lower in the main group than in the controls (Fig. 3). Low density of the detected dopaminergic fibers was predominantly observed in the dorsal aspect of the striatum. Another important finding was moderate gliosis (hypertrophy of GFAP-positive astrocyte projections).
The intensities of staining for class III β-tubulin and TH were low in the myenteric plexus of the rat jejunum (Fig. 4). The levels of phosphorylated α-synuclein (α-Syn-p129) were elevated in the cell bodies of myenteric neurons and in TH-positive fibers (Fig. 5).

**DISCUSSION**

Paraquat holds great promise for PD modeling: some of its properties make paraquat-induced PD models suitable for exploring hypotheses of PD pathogenesis and testing novel drugs [11]. According to the literature, paraquat induces neuronal stress, stimulates production of free radicals in vitro and in vivo, causes elevation of α-synuclein and tau, and promotes deposition of these proteins [8, 12, 13]. Despite the structural similarity between paraquat and MPP⁺ [14], the two neurotoxins enter the brain via different pathways and have different mechanisms of action. Both of them are charged molecules; however, unlike MPP⁺, paraquat is delivered to the brain by a neutral amino acid transporter [15, 16]. Reports of paraquat effects on dopaminergic neurons are controversial. Some authors describe motor dysfunction and death of dopaminergic neurons in rats and mice following systemic administration of paraquat [14, 10, 17]. Others report that experimental animals show no signs of motor deterioration in spite of nigrostriatal pathway degeneration [18, 14]. Although paraquat induces aggregation of α-synuclein and other damage to dopamine-producing neurons of the substantia nigra, it does not have a pronounced effect on dopamine levels in the striatum, which might be due to the compensatory increase in TH activity in this brain region [19].

In rats, paraquat-induced PD is usually modeled by exposing the animals to 10 mg/kg doses of the herbicide dissolved in normal saline. When administered intraperitoneally for 3 weeks, such doses cause selective death of dopaminergic neurons in the substantia nigra, poor motor coordination, reduced muscle tone and contractility [10]. Higher paraquat doses (20–25 mg/kg) are used to model severe damage to internal organs, such as kidneys or lungs [20]. However, our previous experience of exposing Wistar rats to 10 mg/kg paraquat doses for modeling PD was negative: by the time of the 5th injection, all experimental animals (n = 10) had been already dead. Necropsy revealed...
typical paraquat-induced changes in the lungs, kidneys and other visceral organs [20]. In this study, we used 6 mg/kg paraquat doses, which allowed us to avoid animal death and to reproduce behavioral and morphological changes imitating the early manifestations of PD, including motor asymmetry. Asymmetry of motor symptoms (hypokinesia, resting tremors, etc.) is observed at the onset of the disease, but can become less pronounced over time as the disease progresses [21]. Motor asymmetry is instrumental in differentiating PD from other parkinsonian syndromes. At the same time, there have been few reports of asymmetrical damage to substantia nigra neurons in patients with PD [22, 21]. There is also only a scarce description of PD models that recreate motor asymmetry following systemic administration of neurotoxins. Our study fills this gap.

The intensity of staining in the myenteric fibers positive for class III β-tubulin was lower in the main group than in the controls. Although paraquat-induced disruption of microtubule assembly was described previously [23], our data on decreased staining intensity in the fibers positive for class III β-tubulin are inconsistent with the results obtained by some other researchers [6]. Perhaps, our findings do not so much indicate a decline in the absolute number of tubulin-positive nervous fibers, but instead point to a changed morphology of the enteric innervation, i.e. its exhaustion.

The studied brain samples were devoid of TH-containing neuronal bodies; this suggests that TH-positive nervous fibers found in the intermuscular plexus are sympathetic afferents, which is consistent with the reports by other researchers [24, 25]. The intensity of staining for TH was lower in the paraquat group than in the controls, which may indicate damage to sympathetic innervation in the small intestine and low TH content in enteric plexus neurons. Weak staining intensity may reflect changes in fiber density or the functional state of the neurons.

Alpha-synuclein was detected in the peripheral nervous tissue fibers of both experimental and control groups. Under normal conditions, some α-synuclein is present in neurons in the phosphorylated state [26]. In our study, the protein was diffusely distributed in the cell bodies of some myenteric plexus neurons. At the same time, the intensity of neuronal body staining was increased and TH-containing fibers immunopositive for phosphorylated α-synuclein (α-Syn-p129) were thicker in the animals from the paraquat group. Morphological changes observed in nervous fibers and α-Syn-p129 accumulation may be indicative of paraquat-induced production of protein aggregates typically seen in PD. Our findings coupled with previous reports of paraquat-induced α-synuclein overexpression in the substantia nigra [6] emphasize the similarity of molecular pathogenesis of our PD model to the mechanisms of the actual disease.

The possible causes underlying paraquat-induced α-synuclein accumulation in the enteric nervous system include production of reactive oxygen species and inflammation [27]. It was shown previously that inflammatory disorders of the intestine trigger accumulation of phosphorylated α-synuclein in the myenteric plexus neurons of primates [28]. Imbalance between the phosphorylated and non-phosphorylated α-synuclein pools is accompanied by the production of toxic protein fibrils and formation of its insoluble aggregates [29]. Pathologic accumulation of α-synuclein in the fibers innervating the gastrointestinal tract and in the enteric plexus is typical of early PD stages and is regarded as a potential biomarker of the disease [30].

CONCLUSIONS

Systemic administration of 6 mg/kg doses of paraquat to rats induces behavioral and morphological changes similar to those seen in patients with early stages of PD, one of them being α-synuclein pathology in the peripheral nervous system that plays a key role in the pathogenesis of the disease. The proposed regimen is very promising for PD modeling and plays an important role in broadening our understanding of PD pathogenesis and developing novel therapeutic strategies.

References

1. Pringsheim T, Jette N, Frolikis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; (29): 1583–90.
2. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. Nat Rev Dis Primers. 2017; (3): 17013.
3. Chaudhuri KR, Ray, Titova N, editors. Nonmotor Parkinson’s: CONCLUSIONS

Systemic administration of 6 mg/kg doses of paraquat to rats induces behavioral and morphological changes similar to those seen in patients with early stages of PD, one of them being α-synuclein pathology in the peripheral nervous system that plays a key role in the pathogenesis of the disease. The proposed regimen is very promising for PD modeling and plays an important role in broadening our understanding of PD pathogenesis and developing novel therapeutic strategies.

References

1. Pringsheim T, Jette N, Frolikis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; (29): 1583–90.
2. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. Nat Rev Dis Primers. 2017; (3): 17013.
3. Chaudhuri KR, Ray, Titova N, editors. Nonmotor Parkinson’s:
Мак СК, Миронова НА, Учарова С. Нервные клетки головного мозга. Издательство "Медицина", 2015; (6): 4–13.
5. Литература
6. Fergnut PO, Cut J, Mital TM, Halliday GM, Brundin P, Volkman J, et al. Parkinson's disease. Nat Rev Dis Primers. 2017; (3): 17013.
7. Chaudhuri K Ray, Taito N, editors. Nonmotor Parkinson's: The hidden face. International Review of Neurology. Vol. 133. Academic Press, 2017; 794 p.
8. Илларионкин С. Н. Современные представления об этиологии болезни Паркинсона. Неврологический журнал. 2015; (4): 4–13.
9. Jellinger KA. Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci. 2011; (310): 107–11.
10. Manning-Bog A, McCormack AL, Li J, Uversky VN, Fink A, Di Monte DA. Effects of L-dopa and other amino acids on paraquat-induced nigrostriatal dysfunction in vivo. J Biol Chem. 2012; (287): 1841–4.
11. Moretto A, Colosio C. Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease. Nutrotoxicology, 2011; (33): 383–91.
12. Fernagut PO, Hutson CB, Fleming SM, Tetreau NA, Salcedo J, Maslah E, et al. Behavioral and histopathological consequences of paraquat intoxication in mice. Effects of alpha-synuclein overexpression. Synapse. 2007; (61): 991–1001.
13. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem. 2010; (285): 13621–9.
14. Fajizna MA, Shechab S, Nemmar A, Ardem A, Danasekaran S, Hasan MY. Daily Subacute Paracetal Poisoning Exposure Decreases Muscle Function and Substantia nigra dopaminergic Level Physiol Sci. 2013; (62): 312–3.
15. Tieu K. A Guide to Neurotoxic Animal Models of Parkinson's Disease Cold Spring Harb Perspect Med. 2011; (1): a009316.
16. Bus JS, Gibson JE. Paracatal: Model for Oxidant-Initiated Toxicity. Environ Health Perspect. 1984; (53): 37–46.
17. Willis J, Credle J, Oaks AW, Duka V, Lee H, Jones J, et al. Paraquat, but Not Maneb, Induces Synucleinopathy and Tauopathy in Striatum of Mice through Inhibition of Proteasomal and Autophagic Pathways. PLoS ONE. 2012; 7(1): 1–12. DOI: 10.1371/journal. pone.0030745.
18. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thillault C, Langston JW, Cory-Slechta DA, et al. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 2002; (10): 119–27.
19. Shrimizu K, Ohtaki K, Matsuoka K, Aoyama K, Uezato T, Saito O, et al. Carrier-mediated processes in blood — brain barrier penetration and neural uptake of paraquat. Brain Res. 2001; (906): 135–42.
20. McCormack AL, Di Monte DA. Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem. 2003; (85): 82–6.
21. Iizumi Y, Ezumi M, Takada-Takatori Y, Akake A, Kume T. Endogenous Dopamine Is Involved in the Herbicide Paraquat-Induced Dopaminergic Cell Death Toxicological Sciences. 2014; 139 (2): 466–78.
22. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson's disease? Brain Res. 2000; (873): 225–34.
23. Bus JS, Credle J, Oaks AW, Duka V, Lee JH, Jones J, et al. Slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: An animal model of pre-clinical stages of Parkinson's disease? Eur J Neurosci. 2005; (22): 1294–304.
24. Phillips RJ, Pajur JC, Powley TL. Age-related neuronal loss in the submucosal plexus of the colon of Fisher 344 rats. Neurobiol Aging. 2007; (28 (7)): 1124–37.
25. Phillips RJ, Hudson CN, Powley TL. Sympathetic axonopathies and hyperinnervation in the small intestine smooth muscle of aged Fisher 344 rats. Auton Neurosci. 2013; 179 (1–2): 108–121. DOI: 10.1016/j.autneu.2013.09.002.
26. Iizumi Y, Ezumi M, Takada-Takatori Y, Akake A, Kume T. Endogenous Synuclein as a Biomarker of Parkinson's Disease. Front Aging Neurosci. 2012; (4): 105. DOI: 10.3389/fnagi.2012.00105.
27. Iizumi Y, Ezumi M, Takada-Takatori Y, Akake A, Kume T. Endogenous Synuclein as a Biomarker of Parkinson's Disease. Front Aging Neurosci. 2012; (4): 105. DOI: 10.3389/fnagi.2012.00105.
28. Resnikoff H, Metzger JM, Lopez M, Bondarenko V, Mejia A, Simmons H, et al. Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates. J Inflam Res. 2019; (12): 113–26. DOI: 10.2147/JIR.S196552.
29. Zhang J, Li X, Li JD. The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases. Front Neurosci. 2019; (13): 381. DOI: 10.3389/fnins.2019.00381.
30. Yang C, Chen Y, Li M, Wang Y, Zhang W, Chen X, et al. Gastrointestinal 10–22.09.2018: 328–39. DOI: 10.1016/j.autneu.2013.09.002.
31. Junboa Z, Yongtaob Y, Hongboa Li, Fenshuanga Z, Ruyuna L, Chun’avia Y. Experimental study of sucralfate intervention for paraquat poisoning in rats. Environmental Toxicology and Pharmacology. 2017; (53): 57–63.
32. Riederer P, Jellinger KA, Kolper P, Hipp G, Sian-Hulsmann J, Kruger R. Lateralisation in Parkinson disease. Cell Tissue Res. 2018; (373): 297. DOI: 10.1007/s00441-018-2832-z.
33. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. The Lancet Neurology. 2006; 5 (9): 796–802. DOI: 10.1016/s1474-4422(06)70549-x.
34. Li WD, Zhao YZ, Chou IN. Paraquat-induced cytoskeletal injury in cultured cells. Toxicol Appl Pharmacol. 1987; 91 (1): 96–106.
neuroscience.2011.10.042.

27. Toygar M, Aydin I, Agilli M, Aydin FN, Oztosun M, Gul H, et al. The relation between oxidative stress, inflammation, and neopterin in the paraquat-induced lung toxicity. Hum Exp Toxicol. 2015; 34 (2): 198–204. DOI: 10.1177/0960327114533808.

28. Resnikoff H, Metzger JM, Lopez M, Bondarenko V, Mejia A, Simmons HA, et al. Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates. J Inflamm Res. 2019; (12): 113–26. DOI: 10.2147/JIR.S196552.

29. Zhang J, Li X, Li JD. The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases. Front Neurosci. 2019; (13): 381. DOI: 10.3389/fnins.2019.00381.

30. Yan F, Chen Y, Li M, Wang Y, Zhang W, Chen X, et al. Gastrintestinal nervous system α-synuclein as a potential biomarker of Parkinson disease. Medicine (Baltimore). 2018; 97 (28): e11337. DOI:10.1097/ MD.0000000000011337.